Dendritic cell-based cancer immunotherapy targeting MUC-1

Area of Science:

• Immunotherapy
• Oncology
• Vaccine Development

Background:

• Dendritic cells (DCs) are potent antigen-presenting cells (APCs) utilized in cancer vaccine therapy.
• Tumor-associated antigens (TAAs) are crucial for developing effective DC-based vaccines.
• MUC1 is a TAA overexpressed in various hematological and epithelial malignancies.

Purpose of the Study:

• To evaluate the efficacy of autologous DCs pulsed with MUC1-derived peptides in patients with advanced cancer.
• To assess the safety and immunogenicity of this novel cancer immunotherapy.
• To explore potential mechanisms of anti-tumor effects, such as antigen spreading.

Main Methods:

• Identification of two novel HLA-A2 binding 9-mer peptides from the MUC1 TAA.
• Pulsing of autologous DCs with MUC1 peptides for vaccination.
• Clinical studies involving patients with advanced cancer, including metastatic renal cell carcinoma.
• Assessment of cytotoxic T cell activity, immunological responses, and clinical outcomes (e.g., tumor regression).

Main Results:

• Vaccination with MUC1-pulsed DCs generated antigen-specific, HLA-restricted cytotoxic T cells capable of tumor cell lysis.
• The MUC1 peptide-pulsed DC vaccine was well-tolerated with no serious side effects in clinical studies.
• In 20 patients with metastatic renal cell carcinoma, 6 showed regression of metastases, including 1 complete response (CR) and 2 partial responses (PR).
• Responding patients exhibited T cell responses to antigens not included in the vaccine, suggesting in vivo antigen spreading.

Conclusions:

• Autologous DC vaccination pulsed with MUC1-derived peptides can induce both immunological and clinical responses in patients with advanced malignancies.
• This immunotherapy strategy holds potential for treating various cancers overexpressing MUC1.
• Further clinical studies are warranted to optimize treatment regimens for consistent in vivo anti-tumor immune responses.